TGFBR2

PreclinicalBiologic

FFrench Cardiology Society

TGFBR2 is one of 7 biologic programs targeting Aortic Aneurysm. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic AneurysmActive, not recruiting

Aortic AneurysmPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Aortic Aneurysm

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

1 2

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Cleviprex

Chiesi Farmaceutici S.p.A.

Preclinical

1 4

Sufenta

LLeaf Vertical Inc.

Preclinical

—5

Definity

MMicrovascular Therapeutics, LLC

Preclinical

1 6

Blood Taking

CCentre Hospitalier Universitaire de Besancon

Preclinical

1 7

TGFBR2

FFrench Cardiology Society

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aortic Aneurysm1 trial

Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)

Active, not recruiting·FFrench Cardiology Society··NCT05146375·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TGFBR2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TGFBR2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TGFBR2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — French Cardiology Society company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: FFrench Cardiology Society

TGFBR2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aortic Aneurysm1 trial

References

Drug Info

Quick Facts

Related News